Longeveron Adds Seasoned Biotech Executive Todd Girolamo to Its Board of Directors
February 17, 2022 08:00 ET
|
Longeveron
MIAMI, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related...
Longeveron to Participate in Phacilitate Advanced Therapies Week
January 25, 2022 08:00 ET
|
Longeveron
MIAMI, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related...
Longeveron Announces Publication of Lomecel-B Phase 2b Trial Design in Journal of Frailty and Aging
January 12, 2022 08:00 ET
|
Longeveron
MIAMI, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic...
Longeveron Announces Initiation of Phase 2a Clinical Trial of Lomecel-B for the Treatment of Alzheimer’s Disease
January 05, 2022 08:00 ET
|
Longeveron
MIAMI, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic...
Longeveron to Participate in the H.C. Wainwright BioConnect 2022 Virtual Conference
January 04, 2022 08:00 ET
|
Longeveron
MIAMI, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related...
Longeveron Granted Orphan Drug Designation by FDA for Lomecel-B to Treat Infants with Hypoplastic Left Heart Syndrome (HLHS)
December 06, 2021 08:00 ET
|
Longeveron
HLHS is a rare congenital heart defect that affects approximately 1,000 babies in the U.S. per yearOrphan Drug Designation confers certain benefits and may result in seven year market exclusivity upon...
Longeveron Inc. Announces Closing of a $20.5 Million Private Placement
December 03, 2021 16:30 ET
|
Longeveron
MIAMI, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related...
Longeveron Inc. Announces Pricing of a $20.5 Million Private Placement
December 01, 2021 03:17 ET
|
Longeveron
MIAMI, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related...
Longeveron Announces Phase 2 Clinical Trial in Japan to Test Safety and Efficacy of Lomecel-B on Aging Frailty Patients
November 30, 2021 15:20 ET
|
Longeveron
MIAMI, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic...
U.S. Food and Drug Administration Approves Longeveron’s Lomecel-B for Rare Pediatric Disease Designation to Treat Life-Threatening Infant Heart Condition
November 18, 2021 08:00 ET
|
Longeveron
MIAMI, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related...